Adaptive and responsive neuromodulation enters broader clinical testing

Newronika's AlphaDBS reportedly reached a pivotal randomized within-participant comparison with conventional stimulation for Parkinson's disease across Italy, the U.S., and Europe. Preliminary single-center evidence also suggests responsive neurostimulation may be tolerable and effective in older adults with drug-resistant epilepsy, but inconsistent reporting and small samples leave efficacy, safety, durability, and generalizability unresolved.